MedPath

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

Phase 4
Completed
Conditions
Fibromyalgia
Interventions
Drug: Placebo
Registration Number
NCT01014585
Lead Sponsor
Forest Laboratories
Brief Summary

The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple symptoms of fibromyalgia, as demonstrated by changes in symptoms following the discontinuation of milnacipran.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
340
Inclusion Criteria
  • Currently participating in Study MLN-MD-06
  • Receiving a stable dosage of milnacipran (50-200 mg/d) at Screening/Enrollment (Visit 1)
Exclusion Criteria
  • Significant risk of suicide
  • History of mania, bipolar disorder, psychotic disorder, schizophrenia, or a current episode of major depressive disorder
  • Myocardial infarction and/or stroke within the prior 12 months
  • Mean systolic blood pressure > 180 mm Hg or mean diastolic blood pressure > 110 mm Hg at Screening (Visit 1)
  • Active liver disease
  • Severe renal impairment
  • Platelet and bleeding disorders
  • Female patients who are pregnant or breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1PlaceboPlacebo tablets administered orally twice daily
2MilnacipranMilnacipran tablets administered orally twice daily
Primary Outcome Measures
NameTimeMethod
Time to Loss of Therapeutic Response (LTR)From baseline Visit 3 (week 5) to Visit 7 (week 17)

Time to loss of therapeutic response is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a \< 30% reduction in Visual Analog Scale (VAS) pain score from pre-milnacipran exposure OR a worsening of fibromyalgia requiring, in the judgment of the investigator, an alternative treatment

Secondary Outcome Measures
NameTimeMethod
Time to Worsening in Patient Global Impression of Change (PGIC)From baseline Visit 3 (week 5) to Visit 7 (week 17)

Time to worsening in Patient Global Impression of Change is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a PGIC score of 6 or 7. The PGIC is an efficacy assessment on a scale of 1-7 taken at visits 4, 5, 6 and 7. The wording of the assessment is as follows: "Since the start of the study, overall my fibromyalgia is:" 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7=Very Much Worse.

Time to Worsening in Multidimensional Assessment of Fatigue (MAF)From baseline Visit 3 (week 5) to Visit 7 (week 17)

Time to worsening in MAF is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a 10-point increase from baseline in the global index of fatigue in MAF. Scores range from 1 (no fatigue) to 50 (severe fatigue). The MAF contains 16 items measuring 4 dimensions of fatigue: severity, distress, degree of interference in activities of daily living, and timing. Fourteen of the items contain numerical rating scales (increasing in severity); the remaining 2 items have multiple-choice responses (decreasing in severity).

Trial Locations

Locations (58)

Forest Investigative Site 060

🇺🇸

Pembroke Pines, Florida, United States

Forest Investigative Site 009

🇺🇸

Atlanta, Georgia, United States

Forest Investigative Site 008

🇺🇸

Worcester, Massachusetts, United States

Forest Investigative Site 028

🇺🇸

Anderson, South Carolina, United States

Forest Investigative Site 026

🇺🇸

Honolulu, Hawaii, United States

Forest Investigative Site 047

🇺🇸

Seattle, Washington, United States

Forest Investigative Site 025

🇺🇸

Sacramento, California, United States

Forest Investigative Site 032

🇺🇸

Pismo Beach, California, United States

Forest Investigative Site 056

🇺🇸

Libertyville, Illinois, United States

Forest Investigative Site 019

🇺🇸

San Diego, California, United States

Forest Investigative Site 039

🇺🇸

Vista, California, United States

Forest Investigative Site 013

🇺🇸

Ocala, Florida, United States

Forest Investigative Site 007

🇺🇸

Fresno, California, United States

Forest Investigative Site 004

🇺🇸

St. Louis, Missouri, United States

Forest Investigative Site 015

🇺🇸

Chesapeake, Virginia, United States

Forest Investigative Site 050

🇺🇸

Cromwell, Connecticut, United States

Forest Investigative Site 064

🇺🇸

Frederick, Maryland, United States

Forest Investigative Site 011

🇺🇸

Delray Beach, Florida, United States

Forest Investigative Site 035

🇺🇸

Great Neck, New York, United States

Forest Investigative Site 048

🇺🇸

N. Dartmouth, Massachusetts, United States

Forest Investigative Site 027

🇺🇸

Syracuse, New York, United States

Forest Investigative Site 006

🇺🇸

Salt Lake City, Utah, United States

Forest Investigative Site 018

🇺🇸

Greensboro, North Carolina, United States

Forest Investigative Site 017

🇺🇸

Springfield, Massachusetts, United States

Forest Investigative Site 010

🇺🇸

Eugene, Oregon, United States

Forest Investigative Site 024

🇺🇸

Salisbury, North Carolina, United States

Forest Investigative Site 062

🇺🇸

Birmingham, Alabama, United States

Forest Investigative Site 065

🇺🇸

Birmingham, Alabama, United States

Forest Investigative Site 038

🇺🇸

Peoria, Illinois, United States

Forest Investigative Site 040

🇺🇸

Albuquerque, New Mexico, United States

Forest Investigative Site 043

🇺🇸

Palm Harbor, Florida, United States

Forest Investigative Site 002

🇺🇸

Greenville, North Carolina, United States

Forest Investigative Site 003

🇺🇸

Cincinnati, Ohio, United States

Forest Investigative Site 059

🇺🇸

Columbus, Ohio, United States

Forest Investigative Site 005

🇺🇸

Cleveland, Ohio, United States

Forest Investigative Site 044

🇺🇸

Eugene, Oregon, United States

Forest Investigative Site 052

🇺🇸

Medford, Oregon, United States

Forest Investigative Site 046

🇺🇸

Mechanicsburg, Pennsylvania, United States

Forest Investigative Site 036

🇺🇸

Wenatchee, Washington, United States

Forest Investigative Site 041

🇺🇸

Portland, Oregon, United States

Forest Investigative Site 066

🇺🇸

Atlanta, Georgia, United States

Forest Investigative Site 031

🇺🇸

Evansville, Indiana, United States

Forest Investigative Site 049

🇺🇸

Danbury, Connecticut, United States

Forest Investigative Site 016

🇺🇸

Orlando, Florida, United States

Forest Investigative Site 057

🇺🇸

Santa Ana, California, United States

Forest Investigative Site 061

🇺🇸

Kalamazoo, Michigan, United States

Forest Investigative Site 030

🇺🇸

Newton, Massachusetts, United States

Forest Investigative Site 020

🇺🇸

Jackson, Mississippi, United States

Forest Investigative Site 033

🇺🇸

Cherry Hill, New Jersey, United States

Forest Investigative Site 001

🇺🇸

Medford, Oregon, United States

Forest Investigative Site 042

🇺🇸

Winston-Salem, North Carolina, United States

Forest Investigative Site 021

🇺🇸

Greer, South Carolina, United States

Forest Investigative Site 051

🇺🇸

Duncansville, Pennsylvania, United States

Forest Investigative Site 063

🇺🇸

Racine, Wisconsin, United States

Forest Investigative Site 055

🇺🇸

Stamford, Connecticut, United States

Forest Investigative Site 012

🇺🇸

Tucson, Arizona, United States

Forest Investigative Site 014

🇺🇸

Rochester, New York, United States

Forest Investigative Site 054

🇺🇸

Charlotte, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath